Drug Trial Radar · NCT00684970
Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)
Last checked: Nov 19, 2026Latest source record: Dec 5, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100
Planned (sponsor's estimate)
Start
Mar 2009
Primary completion
Feb 2014
Sponsor
- Lead sponsor
- Tiltan Pharma Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 28, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hamsa-1™ is an anti-angiogenic drug combination designed for the treatment of cancer. The investigational product Hamsa-1™ comprises of four well-known active components. The therapy is administrated at a unique dosing regimen that was found to be effective and advantageous in terms of safety.The product is formulated as an oral suspension, conveniently administrated by the patients at home and not requiring medical staff assistance. This Phase IIb clinical trial aims to evaluate the efficacy of Hamsa-1™ for the treatment of metastatic Castration Resistant Prostate Cancer (CRPC) patients.
Conditions
- Metastatic Castration Resistant Prostate Cancer (CRPC)
Interventions
Hamsa-1™ TL-118Drug
Once daily Hamsa-1™ TL-118
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS) measured 24 weeks after treatment initiationTime frame: 24 weeks and up to 3 years
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Bnei Tzion Medical Center
Haifa, Israel · Recruiting
Rambam Medical Center
Haifa, Israel · Recruiting
Sourasky Medical Center
Tel Aviv, Israel · Recruiting
Sheba Medical Center
Tel HaShomer, Israel · Recruiting
Asaf Harofe Medical Center
Tzrifin, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.